Onkologie. 2023:17(4):282-286 | DOI: 10.36290/xon.2023.053

The use of immunotherapy and targeted therapy in Richter's transformation

Tereza Líkařová, Martin ©paček
I. interní klinika - klinika hematologie VFN v Praze a 1. LF UK, Praha

Richter´s syndrome (RS) is a serious complication of chronic lymphocytic leukemia, occurring yearly in 2-10 % of cases. Despite new treatment modalities in the field of haematooncology, RS remains a major clinical challenge. This case report presents a patient in whom disease control was not achieved despite the use of various novel therapeutic approaches. This case thus demonstrates the extremely unfavorable prognosis of RS patients and the clinical urgency of developing new therapeutic approaches.

Keywords: Richter´s syndrome, targeted therapy, immunotherapy, new therapeutic agents.

Accepted: October 3, 2023; Published: October 5, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Líkařová T, ©paček M. The use of immunotherapy and targeted therapy in Richter's transformation. Onkologie. 2023;17(4):282-286. doi: 10.36290/xon.2023.053.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ryan CE, Davids MS. Practical Management of Richter Transformation in 2023 and Beyond. Am Soc Clin Oncol Educ Book [Internet]. 2023;43(e390804) [cited 2023 Jul 1]. doi: 10.1200/EDBK_390804. Go to original source... Go to PubMed...
    2. Briski R, Taylor J. Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era. Cancers (Basel) [Internet]. 2023;15(6):1857 [cited 2023 Jul 1]. doi: 10.3390/cancers15061857. Go to original source... Go to PubMed...
    3. Wang Y, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica [Internet]. 2020;105(3):765-773 [cited 2023 Jul 2]. doi: 10.3324/haematol.2019.224121. Go to original source... Go to PubMed...
    4. Davids MS, et al. Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy. Am Soc Clin Oncol Educ Book [Internet]. 2017;35(15):7505 [cited 2023 Jul 2]. doi: 10.1200/JCO.2017.35.15_suppl.7505. Go to original source...
    5. Rossi D, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood [Internet]. 2011;117(12):3391-3401 [cited 2023 Jul 3]. doi: 10.1182/blood-2010-09-302174. Go to original source... Go to PubMed...
    6. Langerbeins P, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol [Internet]. 2014;89(12):E239-E243 [cited 2023 Jul 4]. doi: 10.1002/ajh.23841. Go to original source... Go to PubMed...
    7. Tsimberidou AM, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol [Internet]. 2006;24(15):2343-2351 [cited 2023 Jul 6]. doi: 10.1200/JCO.2005.05.0187. Go to original source... Go to PubMed...
    8. Kittai AS, et al. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. Blood Adv [Internet]. 2020;4(19):4648-4652 [cited 2023 Jul 6]. doi: 10.1182/bloodadvances.2020002783. Go to original source... Go to PubMed...
    9. Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25). In: Clinicaltrials.gov [Internet]. Updated 2023 Jul 3. [cited 2023 Jul 10]. Available from: Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies - Full Text View - ClinicalTrials.gov.
    10. Kater AP, et al. Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1). Blood [Internet]. 2022;140(Supplement 1):850-851 [cited 2023 Jul 10]. doi: https://doi.org/10.1182/blood-2022-158298. Go to original source...
    11. Eyre TA, et al. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. Lancet Haematol [Internet]. 2021;8(12):e912-e921 [cited 2023 Jul 10]. doi: 10.1016/S2352-3026(21)00305-7. Go to original source... Go to PubMed...
    12. Wierda WG, et al. Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study. Blood [Internet]. 2022;140(Supplement 1):846-849 [cited 2023 Jul 10]. doi: https://doi.org/10.1182/blood-2022-157058. Go to original source...
    13. Ding W, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood [Internet]. 2017;129(26):3419-3427 [cited 2023 Jul 13]. doi: 10.1182/blood-2017-02-765685. Go to original source... Go to PubMed...
    14. Davids MS, et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood [Internet]. 2022;139(5):686-689 [cited 2023 Jul 13]. doi: 10.1182/blood.2021011386. Go to original source... Go to PubMed...
    15. Chanan-Khan A, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol [Internet]. 2006;24(34):5343-5349 [cited 2023 Jul 13]. doi: 10.1200/JCO.2005.05.0401. Go to original source... Go to PubMed...
    16. Rodgers TD, et al. Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma. Br J Haematol [Internet]. 2020;188(4):e33-e36 [cited 2023 Jul 13]. doi: 10.1111/bjh.16302. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.